# BIOTRICITY INC. (BTCY) · Edgar & Edgarette company card

> Biotricity (BTCY) grew revenue 16.0% in FY2026 to $16 million, operating margin 10.6% against a 1.2% median for surgical & medical instruments & apparatus, equity -538% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1630113 · fiscal year ended 2026-03-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/BTCY) · [JSON](https://www.pops4.com/boards/company/BTCY.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $16M |
| Revenue growth, 1 year | 16.0% |
| Revenue growth per year | 20.3% |
| Operating margin | 10.6% (prior year -17.8%) |
| Net margin | -15.0% |
| Operating cash flow | −$718,955 |
| Capital spending | — |
| Free cash flow | — |
| Cash | $149,789 |
| Long-term debt | — |
| Total assets | $6M |
| Total equity | −$35M |
| Equity ÷ assets | -537.9% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -103.09 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Beneish M: -3.48 (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice, late quarterly report notice in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; revenue is hard to predict: its 80% range is ±56%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $16.0M (FY2026). Experience: revenue up 16.0% on the year, up 20.3% a year over 4 years; operating margin 10.6%, up from -17.8%. Soundness: equity -537.9% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $9.7M and $34.9M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $8.9M to $38.2M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin 10.6% against a 1.2% median; growth 16.0% against 11.6%.

Range logged 2026-09-29, receipt c2c9c3f26280326b, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-06-29 ([filing](https://www.sec.gov/Archives/edgar/data/1630113/000149315226030382/0001493152-26-030382-index.htm))
- Item NT 10-Q Late quarterly report notice: 1, latest 2026-08-17 ([filing](https://www.sec.gov/Archives/edgar/data/1630113/000149315226038710/0001493152-26-038710-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-09-28 ([filing](https://www.sec.gov/Archives/edgar/data/1630113/000149315226044407/0001493152-26-044407-index.htm))

## Recent filings

- 8-K · filed 2026-09-28 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1630113/000149315226044407/0001493152-26-044407-index.htm)
- 10-Q · filed 2026-08-19 · [filing](https://www.sec.gov/Archives/edgar/data/1630113/000149315226039209/0001493152-26-039209-index.htm)
- 10-K · filed 2026-07-14 · [filing](https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/0001493152-26-033207-index.htm)
- 8-K · filed 2026-05-01 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1630113/000149315226020939/0001493152-26-020939-index.htm)
- 8-K · filed 2026-02-18 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1630113/000149315226007369/0001493152-26-007369-index.htm)
- 10-Q · filed 2026-02-11 · [filing](https://www.sec.gov/Archives/edgar/data/1630113/000149315226006211/0001493152-26-006211-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001630113.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1630113

## Cite

POPS4, Edgar & Edgarette: BIOTRICITY INC. (BTCY) company card, from the company's own SEC filings, accessed 2026-11-14, https://www.pops4.com/boards/company/BTCY. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.